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Purpose: To develop and validate a diagnostic prediction model for patients with suspected 
giant cell arteritis (GCA).
Methods: A retrospective review of records of consecutive adult patients undergoing temporal 
artery biopsy (TABx) for suspected GCA was conducted at seven university centers. The patho-
logic diagnosis was considered the final diagnosis. The predictor variables were age, gender, 
new onset headache, clinical temporal artery abnormality, jaw claudication, ischemic vision loss 
(VL), diplopia, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and platelet 
level. Multiple imputation was performed for missing data. Logistic regression was used to 
compare our models with the non-histologic American College of Rheumatology (ACR) GCA 
classification criteria. Internal validation was performed with 10-fold cross validation and 
bootstrap techniques. External validation was performed by geographic site.
Results: There were 530 complete TABx records: 397 were negative and 133 positive for 
GCA. Age, jaw claudication, VL, platelets, and log CRP were statistically significant predic-
tors of positive TABx, whereas ESR, gender, headache, and temporal artery abnormality were 
not. The parsimonious model had a cross-validated bootstrap area under the receiver operating 
characteristic curve (AUROC) of 0.810 (95% CI =0.766–0.854), geographic external valida-
tion AUROC’s in the range of 0.75–0.85, calibration p
H–L
 of 0.812, sensitivity of 43.6%, and 
specificity of 95.2%, which outperformed the ACR criteria.
Conclusion: Our prediction rule with calculator and nomogram aids in the triage of patients 
with suspected GCA and may decrease the need for TABx in select low-score at-risk subjects. 
However, misclassification remains a concern.
Keywords: temporal artery biopsy, diagnosis, prediction rule, nomogram, giant cell arteritis, 
validation
Introduction
Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly, and 
may result in irreversible blindness, aortitis, myocardial infarction, stroke, or even 
death. De Smit et al suggest that the incidence of GCA will increase with our aging 
population with an estimated 3 million cases worldwide by the year 2050 as well as 
500,000 patients with blindness at a cost of 76 billion dollars in the US alone.1
GCA can be a diagnostic conundrum, especially when it presents in an occult 
or atypical fashion. To date, there is no specific biomarker for GCA. Blood tests for 
inflammation have very poor specificity, and “seronegative” GCA can occur in up to 
4% of the patients.2 Temporal artery biopsy (TABx) remains the gold standard in the 
diagnosis of GCA, but is an invasive, time-consuming test with suboptimal sensitivity. 
Numerous articles3–7 incorporate the 1990 American College of Rheumatology (ACR) 
classification criteria for GCA8 to guide the decision for TABx. However, the ACR 
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criteria were not meant to be diagnostic criteria,9 and without 
the TABx result, the ACR criteria only have a sensitivity of 
29%. There are many clinical prediction rules in the diagnosis 
and management of patients with suspected GCA,10–16 but few 
were developed using more than 500 TABx or 100 biopsy-
positive GCA cases,17 and few if any have external validation. 
Large collaborative studies can clarify the reliability and 
generalizability of prediction algorithms for patients with 
suspected GCA prior to TABx. We used a large multicenter 
dataset to develop and geographically validate a multivariable 
diagnostic prediction rule for GCA with an accompanying 
spreadsheet calculator and nomogram.
Methods
The consecutive records of subjects undergoing TABx for 
suspected GCA at secondary/tertiary care referral clinics 
were retrieved from four medical centers in ON, Canada; 
two from the US; and one from Switzerland (Table 1). This 
clinical audit was approved by the Michael Garron Hospital 
Research Ethics Board and Queen’s Medical school, and was 
compliant with the Declaration of Helsinki and the TRIPOD 
guidelines.18 Some of the data came from the de-identified 
records of prior research ethics board approved TABx proj-
ects (patient consent was not required by the ethics board),19–22 
and two centers conducted a chart review in July 2017 with 
patient consent. The chart review was not blinded.
This paper only considered cases of biopsy-proven GCA 
(BPGCA). As such the pathologic diagnosis was considered 
the final diagnosis. Healed arteritis was considered as positive 
for GCA. If the pathologic diagnosis was indeterminate, the 
record was considered negative for GCA.
Based on the literature review15,17,23,24 and subject matter 
expertise, the candidate predictors for this study were age, 
gender, jaw claudication, new onset headache, temporal 
artery abnormality on physical examination (tenderness to 
palpation, decreased pulse, and scalp nodularity), diplopia, 
ischemia-related loss of visual acuity or field, or VL 
(a composite of ischemic optic neuropathy, retinal artery 
occlusion, or stroke), platelet level, C-reactive protein (CRP), 
and Westergren erythrocyte sedimentation rate (ESR) prior 
to glucocorticoid initiation.
Polymyalgia rheumatica (PMR) was not included as it 
can be a non-specific clinical manifestation, with overlapping 
age and acute phase response characteristics with GCA. The 
distinction of PMR from osteoarthritis flare can sometimes 
be difficult, and reports of joint X-rays were not uniformly 
available in this study. Except in patients on low-dose pred-
nisone for PMR, bloodwork obtained after glucocorticoid 
initiation was excluded, but later patients were still consid-
ered for multiple imputation analysis. Abnormal ESR was 
defined as Westergren ESR .50 mm/hour. As there was 
variation in the CRP technique (highly sensitive versus rapid/
regular) and upper limit of normal of CRP from different 
labs, each CRP was divided by the upper limit of normal to 
standardize the data.
To avoid overfitting, the minimum estimated sample 
size was found to be 500. With 10 candidate predictors, 
a minimum of 100 events (positive TABx) was required. 
Assuming a utility ratio of four negative TABx for each posi-
tive TABx, the minimum estimated sample size was found 
to be 500 subjects. Missing data at a rate of 10% was antici-
pated, suggesting that at least 550 records would require to 
be reviewed.
Statistical calculations were performed using Stata 14.2 
(StataCorp LLC, College Station, TX, USA), and JMP 
Pro13 (JMP SAS Institute, Marlow, Buckinghamshire, UK) 
Table 1 Characteristics of patients with negative versus positive temporal artery biopsy (n=530)
Factor Negative 
biopsy
Positive 
biopsy
Univariate 
odds ratio
p-value Range 
(low, high)
n 397 133
age in years, mean (sD) 72.9 (10.3) 76.8 (7.8) 1.044 ,0.001 39, 96
Female 270 (68.0%) 88 (66.2%) 0.920 0.69
new headache 289 (72.8%) 101 (75.9%) 1.179 0.48
Temporal arterial abnormality 130 (32.7%) 64 (48.1%) 1.905 0.002
Jaw claudication 73 (18.4%) 63 (47.4%) 3.994 ,0.001
Platelet level, mean (sD) 287 (102) 386 (139) 1.007 ,0.001 53, 940
esr, median (iQr) 35 (16, 57) 53 (34, 74) 1.014 ,0.001 0.01, 240
CrP, median (iQr) 1.6 (0.48, 6.1) 7.8 (2.6, 16) 1.029 ,0.001 0.025, 82.7
Vision loss 72 (18.1%) 47 (35.3%) 2.467 ,0.001
Diplopia 20 (5.0%) 8 (6.0%) 1.206 0.66
Biopsy length in centimeter (n=482) 1.9 (0.7) n=376 1.9 (0.6) n=106 1.179 0.31 0.1, 4.6
Notes: CrP is divided by the upper limit of normal; esr (Westergren) mm/1st hour.
Abbreviations: CrP, C-reactive protein; sD, standard deviation; iQr, interquartile range (25th–75th percentile).
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and α=0.05 was used for statistical significance. Model 
misspecification was evaluated with Stata “linktest” and 
multicollinearity analyzed with Stata “collin” test.
Logistic regression (LR) does not require assumptions 
of normality, although multivariable normality provides a 
more stable solution. To optimize model fit, logarithmic 
transformation of any data that showed skewed distribution 
was examined. The best predictor subsets for the optimized 
full model, with and without log-transformed variables, were 
chosen based on clinical significance and statistical factors: 
p-values, confidence intervals, penalized-likelihood criteria to 
minimize Akaike information criterion (AIC), and minimize 
Bayesian information criterion (BIC), discrimination (area 
under the receiver operating characteristic curve [AUROC]), 
and calibration (Hosmer–Lemeshow goodness of fit, and 
Brier score with Spiegelhalter’s z-statistic) (Table S1).
LR only analyzes complete cases and performs listwise 
deletion. As it cannot be assumed that data was missing 
completely at random (“Discussion” section) multiple 
imputation with 250 imputations was performed to discern 
possible bias, and to determine if there were any discrepan-
cies in the confidence intervals of the predictor variables. 
Multiple imputation using chained equations (MICE) was 
performed on the full model without log transformations, 
as per convention.
As all covariates were clinically important, we retained 
the full model, but we developed a parsimonious model as per 
statistical convention (Tables 2 and 3). The statistically sig-
nificant variables from the optimal full model were selected 
for the parsimonious model. A stepwise regression was 
performed in JMP Pro 13 software with 60% of the data for 
training, 20% for validation, and 20% for testing, using the 
forward direction and combined stopping rules to minimize 
AIC and BIC. Predictor(s) that were statistically significant 
on MICE but not the complete case analysis were forced 
on to the parsimonious model for evaluation. An additional 
nested model excluding the two covariates with the highest 
p-value was made.
Internal validation of the final models was assessed by 
combined cross-fold validation and bootstrap techniques. 
After multivariable LR, 10-fold cross validation was 
performed, and the c-statistic corresponding to each fold 
was averaged. The cross-validated area under the receiver 
operator characteristics (ROC) curve was then bootstrapped 
to determine statistical inference. Three thousand computer-
generated bootstrap samples, each including 530 patients 
from the study were refitted and the average odds ratio 
was obtained.
Geographic external validation was performed by holding 
out the data from each regional contributing center. Since 
large datasets are recommended for external validation,25 if 
a regional dataset had fewer than 30 subjects, then it was 
placed in the combined group (Table 4). One-way analysis 
of variance (ANOVA) was performed to compare the patient 
characteristics in the different regions.
The actual performance of our models at the 5th and 95th 
percentile and Liu optimal cutoff points (Tables 5 and S2) 
were compared with the ACR model. JMP Pro 13 prediction 
profiler was used to compare our models using hypothetical 
examples.
An online spreadsheet calculator was made for both 
models, and a Kattan nomogram was made for the parsi-
monious model.
Length of biopsy was not a primary concern in our initial 
data collection. Recent literature suggests shorter specimen 
lengths are adequate for diagnosis (“Discussion” section) 
and bilateral TABx was routinely performed in patients with 
continued suspicion for GCA if the initial unilateral TABx 
Table 2 Multivariable logistic regression, full model (n=530, pseudo R2=0.256, aUrOC =0.820, phosmer–lemeshow =0.549, 530 jackknife 
replications, 3000 bootstrap replications, log likelihood −222.12)
Predictor β Standard 
error of β
Odds 
ratio 
p-value βbootstrap Standard error 
of βbootstrap
pbootstrap
age in years 0.045 0.014 1.046 0.001 0.045 0.013 0.001
sex (female) −0.152 0.224 0.859 0.559 −0.152 0.269 0.572
new headache 0.231 0.365 1.259 0.426 0.231 0.302 0.446
Jaw claudication 1.296 0.964 3.656 ,0.001 1.296 0.271 ,0.001
Ta abnormality 0.356 0.373 1.428 0.172 0.356 0.270 0.188
Vision loss 1.031 0.787 2.803 ,0.001 1.031 0.286 ,0.001
Diplopia −0.229 0.399 0.795 0.648 −0.229 0.553 0.679
logesr 0.187 0.206 1.206 0.273 0.187 0.154 0.224
logCrP 0.290 0.131 1.337 0.003 0.290 0.091 0.001
Platelets 0.005 0.001 1.005 ,0.001 0.005 0.001 ,0.001
Constant −9.967 0.0000751 0.000 −9.967 1.594 0.000
Notes: Ta abnormality: temporal artery abnormality on clinical exam; logesr, natural logarithm of esr; logCrP, natural logarithm CrP.
Abbreviations: CrP, C-reactive protein; esr, erythrocyte sedimentation rate; Ta, temporal artery.
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was negative.26,27 For completeness sake and to help guide 
the discussion, biopsy length was examined post hoc.
Results
Of the 688 TABx cases retrieved, 530 were complete records 
with 397 being negative and 133 being positive biopsies. 
The TABx dates from the various centers ranged from 
November 2005 to June 2017, and at least 56% of the TABx 
were done after 2010. Forty-eight percent of the patients were 
referred by ophthalmology, and the remainder was referred by 
rheumatology, internal medicine, or primary care centers.
The characteristics of the positive versus negative TABx 
are summarized in Table 1. Patients with positive TABx were 
older and had more jaw claudication, higher platelet level, 
higher ESR, higher CRP, and had more ischemic vision 
loss (VL) compared with the negative TABx group. The 
youngest patient with biopsy-proven GCA (BPGCA) was 
54 years of age. GCA was more common in women, but on 
multivariable analysis, gender, new onset headache, temporal 
artery abnormality, ESR, diplopia, and biopsy length did not 
show a statistically significant difference between positive 
and negative biopsy groups.
Ten patients had BPGCA (10/133=7.5%) with normal 
platelet count (,400 per microliter), ESR ,50 mm/hour, 
and adjusted CRP #1. The subjects with “seronegative” 
BPGCA originated from five different regions, and each case 
was rechecked to ensure the absence of glucocorticoids prior 
to bloodwork. The seronegative BPGCA group had mean 
probability score of 0.108, median of 0.082, and less clinical 
temporal artery abnormality (p=0.012) than their seropositive 
counterparts, but other demographic features including age, 
gender, and biopsy length showed no statistically significant 
difference in the independent t-test.
Data on biopsy length was readily available for 482/530 
(91%) patients that was used for LR. There was no statisti-
cally significant difference found with respect to the length 
of the specimen between the positive and negative biopsy 
groups on univariate LR (p=0.31). Bilateral biopsies were 
performed in 23% of the cases. One patient in the negative 
biopsy group had a TABx length of 0.1 cm, but this was a 
unique case.
Funduscopic findings were readily available for 32 
out of 47 patients with BPGCA and VL. In this group, 23 
(72%) patients had anterior ischemic optic neuropathy, 4 
(12.5%) had central retinal artery occlusion, 4 (12.5%) 
had presumed posterior ischemic optic neuropathy, and 1 
(3%) had a central retinal vein occlusion. We were able to 
retrieve the fundus findings in 26/72 patients with VL and 
Table 3 Multivariable logistic regression, parsimonious model (n=530, pseudo R2=0.248, aUrOC =0.816, phosmer–lemeshow =0.812, 530 
jackknife replications, 3000 bootstrap replications, log likelihood −224.51)
Predictor β Standard 
error of β
Odds 
ratio 
p-value βbootstrap Standard error 
of βbootstrap
pbootstrap
age in years 0.044 0.013 1.044 0.001 0.044 0.012 ,0.001
Jaw claudication 1.402 0.253 4.064 ,0.001 1.402 0.256 ,0.001
Vision loss 0.925 0.268 2.521 0.001 0.925 0.273 0.001
Platelets 0.005 0.001 1.005 ,0.001 0.005 0.001 ,0.001
log CrP 0.358 0.080 1.431 ,0.001 0.358 0.080 ,0.001
Constant −8.496 1.127 1.127 ,0.001 −8.496 1.116 ,0.001
Abbreviations: aUrOC, area under the receiver operating characteristic curve; CrP, C-reactive protein.
Table 4 geographic external validation of full and parsimonious models by regional site
External validation 
set
n (events) Training: 
validation split
Full training 
AUROC
Full validation 
AUROC
Parsimonious 
training AUROC
Parsimonious 
validation AUROC
rochester, Mn, Usa 52 (14) 90:10 0.836 0.688 0.828 0.750
Toronto, On, Canada 124 (21) 77:23 0.820 0.812 0.818 0.805
Ottawa, On, Canada 119 (27) 77:23 0.822 0.794 0.816 0.804
Kingston, On, Canada 172 (32) 68:32 0.836 0.824 0.832 0.845
Composite 63 (39) 88:12 0.816 0.782 0.812 0.793
london, On, Canada 18 (13) 97:3 0.824 0.677 0.823 0.677
Boston, Ma, Usa 20 (10) 96:4 0.825 0.700 0.820 0.750
Zurich, Ch, switzerland 25 (16) 95:5 0.804 0.979 0.802 0.993
Notes: n, number of biopsies at each site; event, positive temporal artery biopsy; Composite, london, On + Boston, Ma + Zurich, Ch.
Abbreviation: aUrOC, area under the receiver operating characteristic curve.
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a negative TABx, and all these patients had non-arteritic 
ischemic neuropathy.
The ESR and CRP levels had skewed distributions, but 
platelet values had a normal distribution. Although LR makes 
no assumptions of normality, model fitting with the log-
transformed ESR and CRP yielded lower AIC and lower BIC 
than any combination of non-transformed/transformed ESR 
and CRP. Multivariable LR showed that age, jaw claudica-
tion, ischemic VL, platelets, and log-transformed CRP values 
were significantly predictive of positive TABx (Table 2) and 
these covariates were later used for the parsimonious model. 
There was no model specification error. There was no mul-
ticollinearity, with mean variance inflation factor (VIF) of 
1.19 in the full model and maximum individual VIF of 1.45 
(Supplementary material).
Twenty-three percent of the records had incomplete 
data, in which serology values were predominantly missing. 
Following were the major missing value patterns: 12% of 
the records had no serology values, 3% of the records had 
missing data regarding platelets and CRP, 3% had missing 
data regarding platelets alone, 2% had missing CRP values, 
and ,1% had missing ESR values. MICE estimates of the 
non-transformed full model with 250 imputations showed 
little bias, if any, with the predictors that were statistically 
significant on complete case analysis, but the temporal 
artery abnormality predictor became statistically significant 
(p
original
 =0.117, p
MICE
 =0.036) and was evaluated for the 
parsimonious model.
Variable selection for statistical modeling was based 
on the following clinical significance and statistical fac-
tors: p-values, the minimum AIC and BIC, discrimination, 
and calibration. The full model with log-transformed CRP 
and ESR had better discrimination and calibration than the 
non-transformed models. There were no statistically signifi-
cant interaction terms. The full model and the parsimonious 
model both had good discrimination (AUROC 0.82), and 
calibration (Figure 1; Table S1) with misclassification rate 
of 17.7%. However, the full model had a false negative rate 
of 54.1% and the parsimonious model had 56.4%. Bootstrap 
sensitivity analysis with 3,000 replications did not reveal any 
discrepancies. (Tables 2 and 3)
The gender and diplopia variables had the highest 
p-values, but when removed from the full model, the eight 
covariate nested model had poor calibration (Reduced 
model A, log transformed). Multiple imputation analysis 
suggested that the temporal artery abnormality variable is 
statistically significant, but its addition in the parsimonious 
model resulted in a poorly calibrated model (Reduced 
model B, log transformed). (Table S1)
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Figure 1 rOC curves for full, parsimonious and aCr models.
Notes: Full model (n=530) phosmer–lemeshow =0.549. Parsimonious model (n=530) 
phosmer–lemeshow =0.812. aCr model = (n=525). phosmer–lemeshow =0.0223 (Five patients 
under the age of 50 years were excluded from logistic regression.).
Abbreviations: rOC, receiver operator characteristics; aCr, american College 
of Rheumatology Classification non-histologic Criteria.
Table 5 Model performance at 5th, 85th and 95th percentile
Performance at 
percentile
5th 95th 85th
Model 
(probability)
Full 
(0.023)
Parsimonious 
(0.033)
ACR 
(0.150)
Full 
(0.782)
Parsimonious 
(0.790)
ACR 
(0.420)*
Full 
(0.514)
Parsimonious 
(0.501)
sensitivity 1.000 0.993 0.901 0.173 0.158 0.256 0.429 0.437
Specificity 0.066 0.081 0.125 0.992 0.992 0.898 0.945 0.952
PPV 0.264 0.266 0.261 0.885 0.875 0.456 0.722 0.753
nPV 1.000 0.970 0.803 0.782 0.779 0.781 0.832 0.834
False negative rate 0 0.008 0.090 0.827 0.842 0.744 0.571 0.564
False positive rate 0.935 0.919 0.875 0.008 0.008 0.102 0.054 0.048
Misclassification rate 0.700 0.691 0.676 0.218 0.217 0.265 0.185 0.178
Notes: *The 95th percentile score for the ACR model is 0.443933, and corresponds with 0% sensitivity, 100%, specificity, unspecified PPV, 75% negative predictive value, 
no false positives, and 100% false negatives. (0.443933 is the maximum possible score and 14% of the data share this score). The next highest aCr probability score is 
0.419872 which is the 85th percentile.
Abbreviations: ACR, American College of Rheumatology Classification non-histologic Criteria; PPV, positive predictive value.
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Internal validation with 10-fold cross validation and 
bootstrap technique showed the following c-statistics: 
0.803 (95% CI =0.757–0.849) for the full model and 0.810 
(95% CI =0.766–0.854) for the parsimonious model.
Five spatial external validations were performed with 
the largest datasets, and the c-statistics ranged from 0.688 
to 0.824 for the full model and from 0.750 to 0.845 for the 
parsimonious model. (Table 4; Figure 2) ANOVA of the 
covariates for the regional datasets showed statistically 
significant difference (all at p,0.001) in clinical temporal 
arterial abnormality, platelets, ESR, CRP, ischemic VL, 
diplopia, and biopsy length between the different centers 
but not for age (p=0.534), gender (p=0.556), jaw claudica-
tion (p=0.239), or new headache (p=0.362). The post-hoc 
pairwise comparisons with Bonferroni correction are shown 
in supplementary material.
The full and parsimonious prediction models had 
similar performance, with almost overlapping ROC curves. 
(Figure 1) Compared to our study models, the ACR model 
has lower sensitivity, specificity, and greater misclassifica-
tion error at almost all cutoff points except the 5th percentile. 
(Tables 5 and S2). The output of the full, parsimonious, and 
the ACR models was compared using hypothetical examples 
(Table 6; Figure 3). The ACR model had a small range of 
probability outputs compared to the study models.
In the full model, no subject with probability score ,0.027 
had a positive TABx, suggesting that 7% of the TABx in this 
study could have been avoided. A probability score of #0.07 
corresponded with a 95% chance of negative TABx and 
approximately 30% of the patients in our negative biopsy 
group had a probability score of #0.07. A probability score 
of 0.23 approximates the 25th percentile of the positive 
TABx group, and a score of 0.43 was the median value of 
the positive biopsy group, and was considered high risk for 
GCA. A probability score of $0.89 was not seen in patients 
with a negative biopsy.
Discussion
Several prediction algorithms for GCA diagnosis have been 
published,8,11,12,17,19,24,28 (Table S3) with the common goal 
of improving diagnostic accuracy and patient selection for 
TABx and for reducing patient morbidity and health care 
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Figure 2 external geographic validation results of the highest (A) and lowest ranking datasets (B).
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expenditures. Compared to other prediction algorithms, 
the following are the strengths and distinguishing features 
of our study:
i) Its large size, validation, and generalizability. Our 
study had sufficient GCA events to support more than 
10 candidate predictor variables with LR. The 0.80 
(95% CI =0.76–0.85) c-statistic from combined internal 
bootstrap cross-validation and multiple imputations 
supports reproducibility of the prediction model. On geo-
graphic external validation, the c-statistic was found to 
range from 0.69 to 0.82 for the full model and even better 
for the parsimonious model. Generalizability is further 
enhanced by the collection of TABx results from seven 
different medical centers with an almost equal proportion 
of patients referred from ophthalmic and non-ophthalmic 
practices.
ii) Its design to independently predict the risk of GCA prior 
to TABx. Although TABx is usually a benign test, it is 
invasive and time-consuming. Ideally risk calculators 
should portend the risk of GCA prior to TABx to guide 
decision making. The ACR criteria8 and other LR 
models11,23 entreaty input of the TABx result or specimen 
length. The performance of our model was also directly 
compared against the 1990 ACR classification criteria.
iii) The employment of four statistically significant objective 
predictors (age, platelets, logCRP, and ischemic VL), the 
first three of which were maintained as continuous vari-
ables to preserve statistical power.29 Prediction algorithms 
Table 6 hypothetical cases comparing the full, parsimonious, and american College of rheumatology models
Clinical scenarios Full model
no vision 
loss
Full model 
with vision 
loss
Parsimonious 
model no 
vision loss
Parsimonious 
model with 
vision loss
ACR 
model
(Case i) 90 yo F
HA + TA Abn JC + 0.80 0.92 0.75 0.88 0.44
Plat 475 ESR 90 CRP 4×
(Case ii) 80 yo F
HA + Ta abn JC + 0.51 0.75 0.56 0.75 0.31
Plat 399 ESR 60 CRP 3×
(Case iii) 80 yo F
HA + Ta abn JC + 0.30 0.55 0.35 0.56 0.31
Plat 250 ESR 60 CRP 2×
(Case iV) 80 yo M
ha: no Ta: no JC + 0.28 0.52 0.35 0.56 0.16
Plat 250 esr 49 CRP 2×
(Case V) 80 yo F
HA + TA + no JC 0.14 0.31 0.11 0.22 0.26
Plat 250 esr 49 CRP 2×
(Case Vi) 80 yo F
HA + Ta: no no JC 0.10 0.24 0.11 0.22 0.16
Plat 250 esr 49 CRP 2×
(Case Vii) 65 yo F
HA + Ta: no no JC 0.06 0.14 0.06 0.13 0.16
Plat 250 esr 49 CRP 2×
(Case Viii) 50 yo M
ha: no Ta: no no JC 0.05 0.14 0.06 0.14 0.31
Plat 390 ESR 55 CRP 2×
(Case iX) 50 yo M
ha: no Ta: no no JC 0.03 0.07 0.03 0.08 0.29
Plat 250 ESR 55 CRP 2×
(Case X) 50 yo F
ha: no Ta: no no JC 0.02 0.06 0.03 0.08 0.15
Plat 250 esr 49 CRP 2×
(Case Xi) 50 yo M
ha: no Ta: no no JC 0.02 0.06 0.03 0.06 0.29
Plat 250 ESR 55 CrP 1
Notes: Parsimonious model: age, jaw claudication, platelets, logCrP, vision loss. The bold indicates the factor that changes as one moves upwards from the bottom of the chart.
Abbreviations: +, present; no, absent; M, male; F, female; ha, new onset headache; Ta, temporal artery; JC, jaw claudication; Plat, platelet level; esr, erythrocyte 
sedimentation rate; esr high, esr $50 mm/hour; CrP, C-reactive protein.
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Figure 3 Prediction risk profile using the full model and Case 4 of Table 6.
Notes: Claudication, jaw claudication; CrP_adj, log (CrP divided by the upper limit of normal CrP). in this hypothetical case, an 80-year-old male has jaw claudication and 
CrP that is elevated twice normal, but no headache, temporal artery tenderness, or diplopia. The esr is ,50, and the platelet levels are normal. The risk of biopsy-proven 
gCa is 28% if there is no vision loss (A), but 52% in the setting of ischemic vision loss (B).
Abbreviations: CrP, C-reactive protein; gCa, giant cell arteritis; esr, erythrocyte sedimentation rate; gCaonBx, biopsy-proven giant cell arteritis.
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Figure 4 nomogram of parsimonious model.
Notes: The length and location of each nomogram scale indicates the relative importance of the predictor variable. a vertical line is drawn down from the value of each 
covariate to determine the score. The sum of the scores is used to determine the probability for a positive temporal artery biopsy.
Abbreviations: CrP, C-reactive protein; Uln, upper limit of normal.
heavily based on patient symptoms23 may be disadvan-
tageous when the physician has cognitive or affective 
biases,30 or when patient responses are ambiguous. Many 
guidelines or prediction rules do not incorporate CRP15,17 
and/or platelet count,8,11 which are more accurate than 
ESR in the diagnosis of GCA.31 Prediction rules that 
incorporate ESR, CRP, and platelet count are laudable13 
but can be improved by the addition of patient symptoms, 
such as jaw claudication.
iv) Provision of an output probability nomogram (Figure 4) and 
online calculator for the risk of GCA (https://docs.google.
com/spreadsheets/d/1wlRFGleW2Vf-LlylmY76KS 
TzIAf1TrX5U_1770HhD1Y/edit?usp=sharing). Prior 
GCA studies have used univariate probability curves,31 
theoretical decision analysis tables,15 scoring systems,13,20 
or risk calculators,11 but many only provide odds 
ratios,12,16,17,24 or likelihood ratios14 that require extensive 
calculation to determine the output probability of GCA. 
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The length and location of our nomogram scales visually 
communicate the statistical importance of each covariate 
and the probability for GCA is enumerated from simple 
addition, rather than odds ratios or likelihood ratios.
Our work agrees with previous studies that have shown jaw 
claudication,12,16,17,23 age,23 and thrombocytosis and elevated 
CRP31,32 to be statistically significant predictors for GCA. The 
odds ratio of 1.005× for platelet level seems outwardly small, 
but platelets were a continuous variable with a wide range. 
For a 50 unit increase in platelets, the odds ratio for positive 
TABx was found to be 1.29×, and for a 100 unit increase in 
platelets, the odds ratio was found to be 1.66×.
We also found that log CRP and ischemic VL were 
useful predictors for GCA. Few prediction rules incorpo-
rate CRP,31,32 in part due to epoch, lack of statistical power, 
and/or missing data.23 In our study, 20% of the patients had 
missing CRP data as it was sometimes not requisitioned 
prior to glucocorticoid initiation, and some practitioners 
only requisition the ESR and not the CRP values in patients 
with suspected GCA or vice versa. In some institutions, the 
result of CRP test takes longer to return than the ESR test, 
and may not be available or recorded prior to referral for 
consideration of biopsy. Some private labs did not offer 
CRP testing. The health care facility where the patient was 
initially assessed may differ from the location where TABx 
was performed, making it more difficult to find the results 
retrospectively. As CRP and other predictors may not have 
been missing completely at random, multiple imputation 
was performed, which did not suggest bias of note in the 
missing data.
VL is one of the most feared complications of GCA, and 
absent from most rheumatology-based prediction schemas. 
In our study, half of the patients were referred by ophthal-
mologists; disc edema and retinal artery occlusion proved to 
be compelling predictors for GCA.
In contrast to other reports,12,24,33 diplopia and new onset 
headache were not statistically significant predictors in 
this study. This may be because VL was a more common 
eye finding, and patients with monocular VL have little or no 
binocular diplopia. Six subjects had diplopia and ischemic 
VL, but only one had BPGCA. Since half of our patients 
originated from ophthalmologists, the complaint of diplopia 
should have been well scrutinized, and this may also account 
for bias compared to some rheumatology studies.
Headache is a common complaint in the elderly with 
up to 51% of the individuals at 65 years of age or older 
have this symptom.34 Although ANOVA did not support 
geographic heterogeneity in the frequency of cephalgia, a 
standardized definition for the new onset headache of GCA 
may render headache a more discriminating predictor. The 
International Classification of Headache Disorders’ criteria 
specifies headache in close temporal relation to other signs 
and symptoms of GCA, worsening of headache in parallel to 
worsening GCA, and improvement of headache after 3 days 
of high dose glucocorticoids.35
Statistical significance should be but one consideration 
in predictive modeling. Although parsimonious models 
save time and facilitate ease of use with nomograms, the 
spreadsheet calculator was generated for the full model; 
each of our study covariates is referenced in the literature as 
clinically significant, and as such, the full model may better 
control for confounding and bias. Although gender was not 
statistically significant, it is an expected control variable 
in most medical studies. The temporal arterial abnormal-
ity predictor variable became statistically significant on 
multiple imputation estimates. Predictors associated with 
a particular hypothesis can be retained, even if they are 
not statistically significant. It was hypothesized that if VL 
was an important predictor of GCA, there would be fewer 
tendencies for binocular diplopia. Our sample was large 
enough such that the covariates with p.0.05 had a negli-
gible effect on the statistical degrees of freedom. Another 
important reason for covariate retention is because variables 
with high statistical significance are not necessarily highly 
predictive, due to different properties of their underlying 
distribution. Sets of variables with predictive power above 
a certain threshold may differ from variable modules iden-
tified by statistical significance-based criterion such as the 
chi-square test.36
Although our study appears to be the largest TABx 
prediction rule study to date, and the only one with external 
validation, the limited size of our external validation (EV) 
sets is a potential weakness. ANOVA showed that six of the 
covariates were statistically significant regional case-mix, 
which likely accounts for the heterogeneous discrimination 
scores. The Rochester group had the lowest EV c-statistic, 
and the lowest proportion of temporal artery tenderness/
decreased pulse, average platelet values, and training vali-
dation ratio (10%). The Mayo series is more likely to be a 
referral cohort, with possible atypical presentations of GCA.17 
The three smallest individual datasets, which comprised 
the “combined” EV set, had a higher proportion of positive 
TABx and may reflect referral bias or selection bias. The 
fair to good EV c-statistics AUROC
EV
 (0.688–0.824 for the 
full model and 0.750–0.845 for the parsimonious model) 
in the setting of diverse regional case-mix suggests that 
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our model is transportable. As our data came from seven 
different centers, the AUROC confidence intervals for the 
bootstrapped 10-fold internal validation (0.757–0.849) for 
the full model and 0.766–0.854 for the parsimonious model 
may be more representative than those from the geographic 
validation. Further collaborative, international studies such 
as the DCVAS37 may achieve the minimum size validation 
sets of 100 events and 100 non-events suggested for EV of 
LR prediction rules.25
Our study had some limitations, which includes its 
retrospective nature with missing data, the constraint to 
BPGCA, and misclassification rate. Retrospective studies 
performed at different institutions may not have uniform 
definitions of jaw claudication, clinical temporal arterial 
abnormality, and recent onset headache, which can be 
inherently subjective assessments. With 10 predictor vari-
ables, missing data was not unexpected in a retrospective 
study. Multiple imputation analysis of the missing data 
showed minimal bias.
This study targets BPGCA. With the exception of 
Grossman,24 most studies do not incorporate biopsy-negative 
GCA (BNGCA). Patients with BNGCA may have more 
headaches and polymyalgia rheumatica but less visual 
complications and jaw claudication than BPGCA and may 
require a different set of decision rules.24,38 TABx is the 
gold standard for BPGCA, but “there are no independent 
validating criteria to determine whether giant cell arteritis 
is present when a temporal artery biopsy is negative”.39 
The schema of Ellis and Ralston,40 was utilized by Vilaseca 
et al41 for BNGCA, but has not been widely applied. Unless 
imaging studies show evidence of vessel abnormality, the 
diagnosis of BNGCA relies on clinical judgment, exhaus-
tive anamnesis,23 and amelioration with systemic gluco-
corticoids in the absence of neoplasm. BNGCA may result 
from inadequate specimen length and skip areas, but routine 
bilateral biopsies are not strongly advocated and specimen 
lengths of 1.5 cm appear to be adequate.42–44 A review of 
240 TABx found that specimen length was not associated 
with the diagnostic yield of TABx.45 Others report fixed 
TABx length of 0.5 cm26 (n=1,520 TABx), 0.7 cm (n=966 
TABx),27 or 1.5 cm46 (n=538 TABx) as the possible optimum 
length threshold TABx length to predict GCA and avoid 
false negative TABx. There was no statistically significant 
difference in the lengths of TABx in the positive or nega-
tive biopsy groups in our study, 90% of which had a fixed 
length .1 cm in both groups.
Although our prediction model outperformed the non-
histologic ACR classification criteria, at a probability cutoff 
point of 0.5, there remained an 18.1% misclassification rate 
with a sensitivity and specificity of 45.9% and 94.2%, respec-
tively. To improve future models, large prospective studies 
or “big datasets” with standardized predictor definitions, 
additional clinical criteria (eg, neck pain, weight loss, fever), 
and objective predictors such as ocular pulse amplitude,21 
OCT ultrasound, MRI of the arteries, HLA-DRB1*04,47 and 
genetic markers should be considered. Alternative predic-
tion schemas such as neural networks10 and support vector 
machine28 can be compared with LR models.
In patients with suspected GCA whose blood results 
have not been clouded by high dose glucocorticoids, a pos-
sible clinical interpretation of the probability values from 
our cohort of 530 patients is summarized in Table 7. Since 
no subject with probability score ,0.024 had BPGCA, 
TABx can probably be avoided in these patients. With 
GCA probability scores ,0.07, the clinician and patient 
may contemplate deferral of TABx and glucocorticoids 
with close observant management. Patients with probability 
scores between 0.7 and 0.23 are at low to moderate risk of 
Table 7 Probability score cutoff points and risk of gCa
Observed 
probability
cutoff point
Full model observed 
percentile
Parsimonious model observed 
percentile
Risk of GCA 
(biopsy-proven)
Negative 
biopsy
Positive
biopsy
Negative 
biopsy
Positive 
biopsy
2.7% 7th 1 4th 1 Very low
7% 31st 5th 26th 5th low
14% 54th 16th 53rd 12th intermediate
23% 75th 25th 73rd 26th Moderate
43% 92nd 50th 91st 49th high
52% 95th 55th 95th 59th Very high
89% 99.9th 96th 99.9th 97th exceedingly high
Notes: results from the online calculator: https://docs.google.com/spreadsheets/d/1wlrFgleW2Vf-llylmY76KsTziaf1TrX5U_1770hhD1Y/edit#gid=0 should be interpreted 
with the cutpoint values in this table. 
Abbreviation: gCa, giant cell arteritis.
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GCA and should be considered for TABx and glucocorticoid 
treatment. Probability scores in the range of 0.24–0.43 are at 
moderate to high risk of GCA, and scores $0.43 are at high 
risk of GCA. Although some may argue that TABx could be 
avoided with a $0.89 probability score, the authors endorse 
pathologic confirmation, given the side effects of prolonged 
glucocorticoid treatment and the occasional alternative 
diagnoses obtained from TABx.
Conclusion
We developed and validated a LR prediction model for 
BPGCA. Jaw claudication, platelet levels, log CRP, ischemic 
VL, and age were statistically significant predictors for posi-
tive TABx. Prediction models are not infallible and cannot 
substitute for clinical acumen or pathologic confirmation. 
However, they organize decision making and help system-
atize the decision to perform TABx.
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